

26 March 2019

## Customer Update re: I123 mIBG

ANSTO has evaluated the equipment failure within our nuclear medicine processing facility which has impacted our ability to supply locally produced I123 mIBG. This equipment failure has not impacted any other products.

The equipment cannot be repaired and replacement of this equipment will require a significant change to the manufacturing process for this product. As a result, we anticipate this outage will remain in place for at least 12 months.

ANSTO will continue to make available I123 mIBG units from Japan to assist in covering the customer orders where flights can enable timely delivery. Current delivery from Japan covers Sydney, Brisbane, Melbourne, Adelaide and Perth. This product will be supplied in line with SAS rules, as the product is not currently approved for use in Australia.

We are also working with our partners to seek alternative methods to support supply for Australian patients. In the meantime, ANSTO will continue to provide I123 to compounding radio-pharmacies as well.

We will continue to work with our customers and assist with guidance on what product options are available. If you have any questions, please contact ANSTO directly on 1800 251 572